“…Recent studies reported that 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ), the most potent endogenous ligand for PPARg, and the synthetic PPARg ligand thiazolidinedione (TZD) can induce terminal differentiation and growth inhibition of human liposarcoma (Tontonoz et al, 1997), breast (Elstner et al, 1998;Yee et al, 1999), prostate (Kubota et al, 1998), colon (Sarraf et al, 1998;Kitamura et al, 1999), gastric (Takahashi et al, 1999;Sato et al, 2000), lung (Chang and Szabo, 2000;Tsubouchi et al, 2000), and pancreas (Motomura et al, 2000;Elnemr et al, 2000) cancer cells, as well as hepatoma cells (Koga et al, 2001) in vitro and in vivo. The in vivo induction of histological and biochemical differentiation of liposarcomas by clinical trial of troglitazone administration was reported by Demetri et al (1999).…”